Abstract
During the past several years, there have been increasing experimental and early clinical observations indicating that allogeneic, and even xenogeneic, mesenchymal stem cells (MSCs) may be useful for cellular cardiomyoplasty. Although the immune tolerance of MSCs is well established in various in vitro studies, controversies on the in vivo immune tolerance of MSCs persist. Confirmation of the feasibility of allogeneic cellular cardiomyoplasty will have vast clinical implications, since it will provide convenient "off-the-shelf" donor cells, as a vehicle for gene therapy, and avoid the need to use dysfunctional autologous MSCs in senile and/or disabled patients.
References
Jan 23, 1996·Proceedings of the National Academy of Sciences of the United States of America·D W BianchiM A DeMaria
Jan 5, 2002·Circulation·Catalin TomaPaul D Kessler
Apr 16, 2002·Science·Polly Matzinger
Jul 18, 2002·The Annals of Thoracic Surgery·Takayuki SaitoRay C J Chiu
Oct 21, 2004·Blood·Sudeepta Aggarwal, Mark F Pittenger
May 18, 2005·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Ray C J Chiu
Jul 7, 2005·Circulation·Wangde DaiRobert A Kloner
Aug 3, 2005·Proceedings of the National Academy of Sciences of the United States of America·Luciano C AmadoJoshua M Hare
Apr 4, 2006·Annals of Medicine·Karl-Henrik GrinnemoGöran Dellgren
Apr 7, 2007·Transplantation·Alain J PonceletPierre Gianello
Apr 24, 2007·Cellular Immunology·Chen-Tao LiuMin Xie
Aug 1, 2007·Blood·Alma J Nauta, Willem E Fibbe
Jan 29, 2008·The Annals of Thoracic Surgery·Rony AtouiDominique Shum-Tim
Citations
Jul 25, 2009·Tissue Engineering. Part C, Methods·Hanayuki OkuraYoshiki Sawa
Jul 31, 2012·Therapeutic Delivery·Ane GarateJose Luis Pedraz
Nov 4, 2011·Journal of Drug Targeting·Thomas J KeanJames E Dennis
Aug 18, 2012·Biochemical and Biophysical Research Communications·Hanayuki OkuraAkifumi Matsuyama
Feb 13, 2010·Journal of Cardiac Surgery·Heather Y McDonald KinkaidRichard D Weisel
Nov 28, 2013·Pharmaceuticals·Takashi Okada, Shin'ichi Takeda